Bibliography
Wollenweber ML, Beyrer K, Baillot A, et al.  The Meningitis and Encephalitis Registry of Lower Saxony, Germany (MERIN) – design and main results of circulating neurotropic pathogen surveillance, 2003 to 2023. Euro Surveill. 2026;31(6):31(6):2500625.

Summary
This surveillance article describes the design, operation, and 21‑year results of the Meningitis and Encephalitis Registry of Lower Saxony (MERIN), a passive, voluntary surveillance system covering Lower Saxony and, since 2011, Bremen, with a combined population of just under 9 million. Established in 2003 after statutory notification for aseptic meningitis ended, MERIN offers free, broad laboratory diagnostics for hospitalized patients with aseptic meningitis, encephalitis, or polio‑like symptoms, aiming to characterize circulating neurotropic pathogens and support polio surveillance.

Between 2003 and 2023, 13,813 patients (34,688 specimens) were investigated; 54.6% were male, and 78.6% were younger than 15 years, with nearly three-quarters of children under 10 and almost half under 5, reflecting the strong pediatric burden of central nervous system infections. Most patients were treated in pediatric wards. Cerebrospinal fluid made up 37.6% of specimens, blood/serum 33.8%, and stool 25.0%, with throat swabs and urine rarely submitted. ​

In 30.2% of patients, at least one causative pathogen was identified; in 69.8%, no pathogen was found, consistent with literature indicating that the etiology of many cases remains unexplained despite extensive testing. Among pathogen‑positive patients (n=4,172), non‑polio enteroviruses (NPEVs) predominated, accounting for 56.9% of diagnoses and occurring in 17.2% of all patients. Borrelia burgdorferi sensu lato (24.1% of pathogen‑positive patients), adenovirus (6.9%), and varicella‑zoster virus (4.6%) were also frequent, whereas herpes simplex virus was detected in only 1.2% of all investigated patients. Tick‑borne encephalitis virus and measles virus were rare, in line with local epidemiology and vaccination.

NPEV subtyping was successful in 54.8% of NPEV infections. Most typable isolates belonged to enterovirus B; 27 genotypes were identified, with echovirus 30, echovirus 6, and coxsackievirus B5 being most common. The system captured known national echovirus 30 and echovirus 6 waves, demonstrating that MERIN mirrors broader German genotype circulation. Enterovirus C and D, including enterovirus D68, were rarely or not detected, and poliovirus was not found, supporting documentation of polio‑free status. ​

Annually, MERIN examined roughly 600 and 900 patients after scale‑up, with peaks in 2008, 2011, 2013, and 2016. Pathogen detection proportions varied by year, with high yields in known outbreak years. A Poisson regression with harmonic terms showed clear summer seasonality in overall pathogens and NPEVs, with marked June–September peaks. During 2020–2021, both detected pathogens and NPEVs declined and seasonal patterns flattened, consistent with reduced circulation under COVID‑19 non‑pharmaceutical interventions, while submission numbers fell less, suggesting high physician acceptance of MERIN.

The authors acknowledge limitations, including voluntary participation, lack of strict case definition, possible selection bias, incomplete clinical feedback, and dependence on the offered diagnostic panel, but conclude that MERIN provides timely individual diagnostics, delineates the spectrum and seasonality of central nervous system pathogens, and serves as an alternative polio surveillance approach in a polio‑free setting.

Comment
This long‑term, laboratory‑based surveillance effort is commendable for sustaining a robust platform over two decades in a disease area that is comparatively rare but often severe and life‑altering, particularly for the predominantly pediatric patient population. By systematically characterizing meningitis, encephalitis, and polio‑like diseases, the authors underscore that low incidence does not equate to low public health relevance when lifelong neurological sequelae are possible. An important added value of this work is that many documented pathogens are, in principle, vaccine‑preventable, including mumps, tick‑borne encephalitis, varicella, and adenovirus, while others, such as Borrelia burgdorferi, are active targets of vaccine development. For non‑polio enteroviruses, the detailed subtype information generated here illustrates both the current diagnostic strength and the need for even more granular genotype‑specific data as future vaccines or other targeted interventions are considered. Overall, this study deserves praise for linking high‑quality clinical surveillance with clear implications for vaccination and pathogen‑specific prevention strategies.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Norris RS, Egeskov-Cavling AM, Franck KT, Nygaard U, Fischer TK, Johannesen CK. Incidence, risk factors, and costs of neonatal enterovirus hospitalizations in Denmark. Int J Infect Dis. 2026; 164:108417.

Summary
This nationwide, register-based case-control study from Denmark quantifies how often neonatal enterovirus (EV) infections lead to hospitalization, which infants are at highest risk, and what these episodes cost the health system. Over nine years (2015–2023), the authors included the complete national birth cohort of 544,168 neonates and linked multiple high-quality registries using unique personal identifiers. Neonatal EV hospitalizations were defined by either a laboratory-confirmed positive EV test with a temporally related admission or an EV-related ICD-10 diagnosis, with overlap carefully handled to avoid double-counting.

A total of 181 neonates met the EV case definition, corresponding to an incidence of 34 hospitalizations per 100,000 live births. There was considerable year-to-year variation, with peaks in 2018 and 2023, and the highest annual incidence reached 60 per 100,000 live births in 2023. The clinical picture was frequently severe: nearly half of the infants (48%) had central nervous system (CNS) involvement, and 20% had sepsis; 9% had both CNS disease and sepsis. Median length of stay was 3.5 days overall, but longer for CNS and sepsis categories, particularly CNS infection with or without sepsis.

Seasonality emerged as a key determinant. Eighty-two percent of admissions occurred between June and November, with prominent peaks in September, October, and November, and very low case numbers during winter and early spring. The authors also found that neonates who were not first-born had more than twice the odds of EV hospitalization compared with first-born infants, even after adjustment for other covariates. This is consistent with the hypothesis that older siblings, especially those in daycare or school, introduce EV into the household, with subsequent transmission to vulnerable neonates. Gestational age and major perinatal indicators (including Apgar scores and mode of delivery) were not strong drivers of risk, and congenital anomalies were uncommon among cases, suggesting that severe neonatal EV infection can occur in otherwise healthy term infants. The authors emphasize that EV testing in neonates is usually reserved for more severe presentations, particularly suspected meningitis, encephalitis, or sepsis-like illness, so their cohort is likely enriched for severe disease; milder EV infections are presumably underdiagnosed and managed in outpatient settings or not recognized at all.

The economic analysis used diagnosis-related group tariffs (2024 values) to estimate direct hospital costs. Across the study period, total neonatal EV hospitalization costs were approximately €5.3 million, with an average of €29,213 per patient. CNS infections without sepsis were the most expensive category, with mean costs around €41,977 per patient, while combined CNS infection and sepsis had the highest per-patient cost, exceeding €60,000 on average, despite smaller case numbers. Cost peaks in 2018 and 2023 reflected higher case counts and longer lengths of stay, whereas in 2020, during COVID-19, fewer but more severe cases resulted in the highest cost per patient.

The authors acknowledge several limitations, including potential under-ascertainment of mild cases, residual confounding due to limited data on household composition and behaviors, and cost estimates restricted to direct hospitalization costs without long-term sequelae or societal costs. Nonetheless, the use of national data, linkage of clinical and laboratory records, and a matched control group provide robust estimates of incidence, risk factors, and direct costs. The study concludes that while neonatal EV hospitalizations are rare events at the population level, they are clinically significant, seasonally patterned, and economically burdensome, especially when CNS is involved. This, the authors argue, justifies heightened clinical vigilance in late summer and autumn, particularly for neonates with older siblings, and supports consideration of targeted preventive strategies, including exploring EV vaccines and antiviral therapies.

Comment
This study delivers precisely what clinicians and policymakers need for neonatal enterovirus: hard numbers. It confirms that severe neonatal EV disease is uncommon in a high-income setting—on average 34 hospitalizations per 100,000 live births—but when it happens, it is often serious and expensive, dominated by meningitis and sepsis with substantial per-case costs. For bedside practice, the message is straightforward: in late summer and autumn, especially in later-born neonates with older siblings, EV should sit high on the differential for fever, sepsis-like presentations, and neurologic symptoms.

The more provocative question is whether such a rare condition justifies vaccine development. On incidence alone, the answer might appear no: even a perfectly effective neonatal EV vaccine would prevent relatively few hospitalizations per birth cohort in Denmark. However, the picture is more nuanced. First, these data represent only one country; global burden, particularly in low- and middle-income settings with higher transmission and less intensive supportive care, may be substantially greater. Second, the authors rightly highlight that current cost estimates exclude long-term neurologic sequelae after neonatal EV meningitis or encephalitis, as well as indirect societal costs. If future studies demonstrate a meaningful rate of neurodevelopmental impairment, the cost–benefit calculus could shift.

That said, broad-spectrum EV vaccines face formidable technical and programmatic hurdles: antigenic diversity, the need for early-life or even maternal immunization, and competition for resources with pathogens of higher and more clearly quantified burden. The most realistic near-term implication of this work is not a stand-alone EV vaccine, but a stronger case for targeted surveillance, improved diagnostics, and possibly inclusion of EV in multivalent platforms if such technologies emerge. For now, the rarity of clinically recognized neonatal EV in high-income countries argues for cautious prioritization: vigilance and better data first, vaccines only if global burden and preventability are convincingly demonstrated.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Wang JJ, Schönborn L, Warkentin TE, et al. Adenoviral inciting antigen and somatic hypermutation in VITT. N Engl J Med. 2026;394(7):669-683.

Summary
This mechanistic study investigates why a tiny fraction of recipients of adenoviral vector–based COVID‑19 vaccines (ChAdOx1‑S or Ad26.COV2.S), and some patients with natural adenovirus infection, develop vaccine‑induced immune thrombocytopenia and thrombosis (VITT), a severe prothrombotic syndrome mediated by platelet‑activating antibodies against platelet factor 4 (PF4). The authors hypothesized that VITT arises from a misdirected, boosted immune response against an adenoviral antigen that cross‑reacts with PF4 in genetically predisposed individuals. They combined antibody proteomics and genomics to characterize anti‑PF4 antibodies from 21 patients with VITT, sequenced immunoglobulin light‑chain genes from 100 patients, and systematically mapped antibody binding to adenoviral structural proteins, especially the highly conserved core protein VII (pVII), which binds viral DNA and shares biochemical features with PF4.

Mass‑spectrometric sequencing of purified anti‑PF4 antibodies showed a strikingly stereotyped molecular signature: virtually all pathogenic VITT antibodies used the same immunoglobulin lambda light‑chain family, IGLV3‑21, specifically alleles *02 or *03, and displayed a conserved acidic motif (DDSD) in LCDR2 plus a recurrent somatic hypermutation at position 31 of the light‑chain CDR1, substituting germline lysine (K) with glutamic acid (E) or, less often, aspartic acid (D). In the heavy chain, different IGHV families were used, but HCDR3 length and the presence of an acidic ED motif were highly conserved, generating a strongly negatively charged paratope that can bind the positively charged PF4. Germline sequencing in 100 patients confirmed that position 31 is lysine in all cases and that E/D31 is a somatic mutation rather than a germline polymorphism.

To test functional causality, the authors reverse‑engineered two human recombinant VITT antibodies (CR22046 and CR23004) from patient sequences. These antibodies bound PF4 but not PF4–heparin complexes, and in vitro they activated platelets in a PF4‑dependent fashion. In a human PF4/human FcγRIIa transgenic mouse model, CR22046 caused profound thrombocytopenia (≈80% platelet drop) and thrombosis at typical VITT sites (cerebral venous sinus, splanchnic veins, pulmonary embolism). When the key light‑chain mutation was reverted to germline (E31K), both recombinant antibodies largely lost PF4 binding, required very high concentrations to activate platelets in vitro, and induced thrombosis in only a minority of mice, with platelet counts similar to controls. A second engineered variant that replaced the DDSD motif (alleles *02/03) with the YDSD motif encoded by IGLV3‑2101/*04 abolished PF4 binding and platelet activation, underscoring the requirement for both the specific allele and the K31E/D mutation for full pathogenicity.

To identify the adenoviral trigger, the authors purified antibodies from VITT sera using immobilized ChAdOx1 virions and individual adenoviral proteins (penton, pIIIa, pV, pVI, and pVII). Antibodies against intact virions did not show clonotypes matching the pathogenic anti‑PF4 fingerprint and did not cross‑react with PF4, arguing against a surface capsid antigen as inciting epitope. In contrast, IgG purified against recombinant pVII contained clonotypic species whose light‑ and heavy‑chain CDR3 “barcodes” matched those of anti‑PF4 antibodies from the same patient. These anti‑pVII antibodies cross‑reacted with PF4, and conversely, purified anti‑PF4 antibodies bound pVII. Importantly, anti‑pVII antibodies from a healthy vaccine recipient lacked this cross‑reactivity, indicating that cross‑reactive clones are specific to VITT.

Using a library of overlapping 15‑mer peptides spanning ChAdOx1 pVII, they mapped the shared epitope to a highly basic linear sequence (RYARAKSRRRRIARR) in the central region of pVII. Recombinant VITT antibodies bound strongly to this peptide, whereas the back‑mutated E31K variant bound the peptide more strongly than PF4, supporting the idea that the germline antibody is primarily anti‑pVII and only with the K31E/D mutation acquires high‑affinity PF4 binding. The epitope sequence is nearly identical in Ad26 pVII, providing a structural explanation for VITT after both ChAdOx1‑S and Ad26.COV2.S. Structural modeling showed that the acidic paratope formed by the DDSD motif and E/D31 faces the basic PF4 surface, enabling high‑avidity binding and formation of large PF4–IgG immune complexes capable of clustering PF4 and cross‑linking platelet FcγRIIa receptors, the hallmark of VITT pathophysiology.

The authors integrate these findings into a two‑hit model. First, in genetically predisposed individuals (carrying IGLV3‑21*02/*03), natural adenovirus infection primes B cells specific for the basic epitope on pVII, generating a polyclonal anti‑pVII response with germline K31. Second, during adenoviral vector vaccination (or reinfection), booster stimulation and somatic hypermutation in rare B‑cell clones introduce K31E/D, converting some anti‑pVII antibodies into high‑avidity anti‑PF4 antibodies that still weakly recognize pVII but now preferentially bind PF4, forming pathogenic immune complexes and triggering VITT. The rarity of the required genetic background plus the specific somatic event explains the extremely low incidence of VITT. The authors emphasize that other anti‑PF4 disorders (heparin‑induced thrombocytopenia, CMV‑associated anti‑PF4 disease) likely involve different viral or drug epitopes and may or may not share similar genetic constraints. They propose that redesigning adenoviral vectors to alter pVII or replace it with a non‑mimicking analogue could eliminate this upstream trigger, potentially preserving the platform’s advantages while reducing VITT risk.

Comment
Clinically, this work does not change acute VITT management, but it clarifies why VITT is tightly linked to adenoviral vectors, why it is so rare, and why anti‑PF4 antibodies in most vaccinated individuals are non‑pathogenic. For future products, it provides a roadmap for rational adenoviral vector re‑engineering and suggests that, in principle, genetic or serologic risk stratification might one day identify individuals at highest VITT risk—though such testing is far from ready for routine use.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Novick DR. A pediatrician’s dilemma—pushing back against CDC guidance in the exam room. N Engl J Med. 2026;394(7):632-633. doi:10.1056/NEJMp2517911.

Summary
In this Perspective, Novick describes a clinical encounter with a long‑standing patient, now a pregnant mother, who refuses all vaccines for her child, citing the Centers for Disease Control and Prevention (CDC) as her source of doubt and confusion. The author, a pediatrician with 30 years of experience, finds herself unusually at a loss for words—not because of the familiar content of vaccine hesitancy, but because the CDC, previously her trusted authority, has become the parents’ rationale for rejecting evidence‑based vaccination. The essay is set against the backdrop of a “current administration” that has reshaped the CDC’s vaccine messaging and policies, including implying a link between MMR and autism and weakening recommendations for hepatitis B and other vaccines, thereby undermining long‑standing immunization norms.

In the exam room, the pediatrician attempts to re‑center the conversation with the mother on evidence, reassurance, and shared values, while recommending alternative trusted sources such as the American Academy of Pediatrics (AAP), her own practice, and local experts. Novick outlines her options: continue to counsel firmly and risk damaging a relationship that spans generations; discharge the family from her practice, an approach that AAP now accepts in some cases; or intentionally “warm the room” and preserve the relationship in hopes of future progress. She chooses the latter in this encounter, pivoting to neutral topics while recognizing the discomfort of walking multiple “fine lines” at once: discrediting federal health agencies while remaining ostensibly apolitical, emphasizing evidence while practicing patient‑centered care, and protecting children while contemplating narrowing her patient panel.

The piece closes with the author’s own “fierce protective instinct,” informed by personal experience with children lost or critically ill from vaccine‑preventable infections, and her fear that the politicization of the CDC will undermine decades of progress in public health.

Commentary
This is a powerful, unsettling snapshot of how politicized guidance from a once‑trusted agency can reverberate directly into the exam room and erode vaccine confidence even among previously hesitant‑but‑persuadable parents. For clinicians, it crystallizes the emerging need to decouple their own authority from that of federal agencies while still advocating strongly—and persistently—for evidence‑based immunization.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Banooni P, Gonik B, Epalza C, et al; GRACE Study Group. Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein–based vaccine. Clin Infect Dis. 2026;82(1):e146-e155.

Summary

This phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy, immunogenicity, and safety of an investigational unadjuvanted maternal RSV prefusion F protein–based vaccine (RSVPreF3-Mat) in pregnant women and their infants across 24 countries, including both low- and middle-income countries (LMICs) and high-income countries (HICs). Women aged 18–49 years with singleton uncomplicated pregnancies at 24⁰/₇–34⁰/₇ weeks’ gestation were randomized 2:1 to receive a single intramuscular dose of RSVPreF3-Mat or placebo. The primary endpoints were efficacy against medically assessed RSV-associated lower respiratory tract disease (MA–RSV–LRTD) of any severity and severe MA–RSV–LRTD in infants up to 6 months after birth, and safety in infants up to 12 months of age. Immunogenicity in mothers and infants and additional efficacy endpoints (e.g., RSV hospitalization, all-cause LRTD) were secondary objectives.

A total of 5345 women were randomized, and 5328 received the study intervention (3557 vaccine, 1771 placebo); 5235 infants were enrolled (3494 vaccine, 1741 placebo). Just over half of participants were from LMICs, and baseline characteristics were generally balanced between groups, apart from a higher proportion of preterm births later observed in the vaccine arm. Trial enrollment and vaccination were stopped prematurely in 2022 after a safety signal of increased preterm birth and neonatal death in the vaccine group was detected; however, follow-up continued to the planned end (6 months postpartum for mothers, 12 months postbirth for infants).

In infants born ≥4 weeks after maternal vaccination (primary efficacy population; 3426 vaccine, 1711 placebo), RSVPreF3-Mat showed substantial protection during the first 6 months of life. Vaccine efficacy (VE) against any MA–RSV–LRTD was 65.5% (95% credible interval [CrI], 37.5%–82.0%), and VE against severe MA–RSV–LRTD was 69.0% (95% CrI, 33.0%–87.6%). VE against RSV-associated hospitalization up to 6 months was 50.1% (95% CrI, −3.6% to 75.8%), with a wide CrI crossing zero owing to the limited number of events. Protection waned over time: cumulative VE against any MA–RSV–LRTD and severe MA–RSV–LRTD remained statistically supported (CrI lower bound >0) until approximately 9 and 7 months, respectively, but by 12 months, VE estimates had declined to 23.0% and 14.8%, with CrIs including zero.

Regional analyses suggested higher efficacy in HICs than LMICs. VE against any MA–RSV–LRTD to 6 months was 75.9% (95% CrI, 46.1%–91.5%) in HICs and 47.8% (95% CrI, −25.8% to 77.3%) in LMICs, with similar patterns for severe disease. The authors note that these subgroup analyses were descriptive and not powered for formal comparisons; potential contributors to lower apparent VE in LMICs include differences in exposure intensity, co-morbidities, and factors influencing transplacental antibody transfer.

Immunogenicity data from a defined subcohort (518 mothers, 571 infants in the vaccine group; 256 and 274, respectively, in the placebo group) showed robust boosting of maternal RSV-A neutralizing antibodies and efficient transplacental transfer. Maternal geometric mean titers (GMTs) rose from approximately 637 (ED₆₀) pre-vaccination to about 9200 one month post-vaccination (geometric mean ratio [GMR] ≈15), and remained ~5700 at delivery (GMR ≈9.6 vs baseline). In infants of vaccinated mothers, RSV-A neutralization GMTs at birth were markedly higher than in the placebo group (≈9500 vs 700), declining over 6 months but staying clearly above placebo values. The geometric mean transplacental transfer ratio of RSVPreF3-binding IgG was ~1.46 in the vaccine group, with ~87% of infants showing a transfer ratio ≥1, indicating active and generally efficient IgG transport. Transfer ratios were numerically lower in LMICs thanin  HICs, but higher maternal titers in LMICs resulted in similar infant titers.

Safety analyses revealed acceptable reactogenicity: solicited local reactions (particularly injection-site pain) were more frequent with RSVPreF3-Mat than placebo, while solicited systemic reactions (fatigue, headache, fever) were broadly similar and usually mild or moderate. Unsolicited adverse events (AEs) within 30 days and serious adverse events (SAEs) up to 6 months postpartum in mothers and 12 months in infants occurred at similar frequencies in vaccine and placebo groups.

However, pregnancy-related AEs of special interest identified a higher rate of pathways to preterm birth (7.0% vs 5.3%) and a higher rate of preterm delivery (<37 weeks’ gestation) in the vaccine group (6.8% vs 4.9%), corresponding to a relative risk of 1.37 (95% CI, 1.08–1.75). Neonatal deaths were also more frequent in the vaccine arm (13 vs 3), predominantly in LMICs, and largely among preterm infants; investigators considered most infant deaths related to prematurity rather than directly to vaccination. No maternal or infant deaths were judged vaccine-related. Despite extensive investigation, no clear biological mechanism linking RSVPreF3-Mat to preterm birth was identified. Given the observed imbalance and its clinical significance, the sponsor terminated further development of this maternal RSV vaccine candidate.

Comment
The above commentary provides a succinct and timely synthesis of how a single lineage, GPSC10, exemplifies modern pneumococcal vaccine escape, and it succeeds in shifting the reader’s focus from serotypes alone to the underlying genomic lineages. Its main strengths are the clear articulation of the three “dangerous” features of GPSC10—capsular switching, invasiveness and multidrug resistance—and the use of diverse regional examples to show how the same lineage can present as different serotypes in different epidemiologic contexts. The tables summarizing GPSC10‑mediated replacement and vaccine coverage against GPSC10‑linked NVTs are particularly useful for policy discussions, making explicit where current higher‑valent PCVs still have blind spots.

However, the evidence base is entirely observational, which means the associations described between PCV use, lineage shifts and resistance patterns cannot, by themselves, establish causality—this is a major limitation of such analyses. That said, the consistent temporal sequence of events across settings and the strong biological plausibility of vaccine‑driven selection make a causal relationship not only plausible but, to many readers, quite convincing. As a commentary, it remains inherently descriptive and depends on previously published genomic and epidemiologic studies without providing new data or quantitative risk estimates. Important issues such as the comparative contribution of GPSC10 versus other lineages to residual IPD, or modelling of the potential impact of pediatric PCV20 or future pediatric PCV21, are only implied rather than explored. The discussion of policy implications remains relatively general; more concrete guidance on surveillance design, data sharing, and how to prioritize serotypes in next‑generation vaccines would strengthen its utility for ministries of health and advisory groups.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Veeraraghavan B, Varghese R, Gurumoorthy M. Beyond serotypes: Why GPSC10 redefines vaccine escape in the pneumococcal vaccine era. Vaccine. 2026; 74:128238.

Summary
This commentary examines how the pneumococcal lineage GPSC10 has emerged as a prototypical “vaccine‑escape” lineage in the era of pneumococcal conjugate vaccines (PCVs), arguing that lineage‑based genomic surveillance is now as important as serotype‑based monitoring. The authors begin by recalling that PCVs have substantially reduced invasive pneumococcal disease (IPD) due to vaccine serotypes (VTs), but their ecological success has been offset by the rise of non‑vaccine serotypes (NVTs), a phenomenon termed serotype replacement. Serotype replacement can occur either by expansion of existing NVTs that occupy the ecological niche vacated by VTs or by capsular switching, whereby a lineage acquires a new capsular locus and thus “changes” serotype under vaccine pressure. Because the same genomic lineage can express both VTs and NVTs, the paper argues that genomic frameworks such as Global Pneumococcal Sequence Clusters (GPSCs) are essential to understand vaccine impact, disease persistence, and spread.

Within this framework, GPSC10 is highlighted as a lineage of special concern because it combines three properties: ability to undergo capsular switching, high invasive disease potential, and multidrug resistance (MDR). GPSC10 encompasses at least 17 serotypes, including both vaccine and non‑vaccine serotypes (3, 6A, 6C, 7B, 10A, 11A, 13, 14, 15B, 15C, 17F, 19A, 19F, 23A, 23B, 23F, and 24F). Historically, it expanded as serotype 19A, a key PCV7 escape serotype, but after PCV13 introduction, the same lineage has increasingly been expressed as NVTs such as 24F, 10A, and 15B/C in different regions. This allows GPSC10 to evade serotype‑specific immunity induced by PCVs while maintaining its underlying genetic determinants of virulence and resistance. Capsular switching events within the lineage, for example, from serotype 14 to 11A in Indian data, further illustrate its adaptive capacity.

The commentary then dissects the three core attributes that make GPSC10 a vaccine‑escape threat. First, serotype replacement and capsular switching together alter serotype distribution over time; under vaccine‑induced selective pressure, NVTs that are carried by successful lineages can expand and undermine overall vaccine effectiveness, especially when they are more virulent or resistant. Second, GPSC10 has demonstrated high invasiveness, particularly in its 24F expression. In France, GPSC10‑24F has been disproportionately associated with meningitis compared with other NVTs, highlighting that lineage replacement is not just about carriage prevalence but also about disease propensity. Third, the lineage frequently carries MDR to penicillin, cotrimoxazole, macrolides, tetracycline and sometimes fluoroquinolones, enabling it to thrive under antibiotic pressure and expand once PCVs reduce competing VT lineages. In South Africa, the expansion of GPSC10 lineages expressing serogroup 24 and 10A has paralleled rising MDR rates, while European GPSC10‑24F isolates likewise harbor multiple resistance determinants

Geographical and strain‑level factors in lineage expansion are discussed, drawing heavily on recent genomic and epidemiologic studies. After PCV introduction, VTs show reduced relative fitness while NVTs gain a growth advantage, consistent with serotype replacement dynamics. GPSC10’s particular advantage lies in combining both VT and NVT expressions with MDR traits. Early PCV roll‑out reduced penicillin resistance by targeting classical resistant VTs, but subsequent expansion of resistant NVTs has eroded this benefit. Modelling work incorporating human mobility suggests that most pneumococcal strains initially spread locally, but later generations increasingly disseminate to distant municipalities; large urban centers act as hubs, and variants originating in rural areas may ultimately travel farther, patterns that have implications for GPSC10 spread.

Regional snapshots illustrate how GPSC10 has manifested differently across continents. In France and Spain, PCV13 introduction was followed by a rapid switch from GPSC10‑19A to GPSC10‑24F, driving nationwide pediatric IPD surges dominated by 24F. In Pakistan, post‑PCV13 data show declines in 19A/19F but expansion of GPSC10‑10A in both carriage and disease, highlighting adaptation to local serotype niches. Indian genomic surveillance suggests an emerging role of GPSC10, mainly with serotype 15B/C, with recent reports of rising 15B/15C disease albeit without genomic confirmation in all instances. In South Africa, GPSC10 expansion has involved serogroup 24 and 10A, with broader serotype diversity than in Europe and tight linkage to MDR. Newly published data from the Netherlands, Malawi, Ethiopia and Tunisia add further examples of GPSC10‑related vaccine escape profiles involving serotypes 19A and 3, again often coupled with resistance.

The article closes by linking these observations to current and pipeline vaccines. A concise comparison shows that PCV15 (Vaxneuvance) does not cover GPSC10‑linked NVTs 24F, 10A or 15B/C; PCV20 (Prevnar20) covers 10A and 15B (with cross‑protection to 15C via de‑O‑acetylated 15B) but still omits 24F; and the adult‑only PCV21 (Capvaxive) is the first to include 24F and 10A plus several other emerging NVTs, yet is not indicated for pediatric use. The authors argue that GPSC10 epitomizes the “next frontier” of pneumococcal vaccine escape and that its diverse regional replacement trajectories (24F in Europe, 10A in Pakistan, 15B/C in India, broader NVT mix in South Africa) underscore the need for sustained, country‑specific genomic surveillance to inform vaccine policy.

Comment
The above commentary provides a succinct and timely synthesis of how a single lineage, GPSC10, exemplifies modern pneumococcal vaccine escape, and it succeeds in shifting the reader’s focus from serotypes alone to the underlying genomic lineages. Its main strengths are the clear articulation of the three “dangerous” features of GPSC10—capsular switching, invasiveness and multidrug resistance—and the use of diverse regional examples to show how the same lineage can present as different serotypes in different epidemiologic contexts. The tables summarizing GPSC10‑mediated replacement and vaccine coverage against GPSC10‑linked NVTs are particularly useful for policy discussions, making explicit where current higher‑valent PCVs still have blind spots.

However, the evidence base is entirely observational, which means the associations described between PCV use, lineage shifts and resistance patterns cannot, by themselves, establish causality—this is a major limitation of such analyses. That said, the consistent temporal sequence of events across settings and the strong biological plausibility of vaccine‑driven selection make a causal relationship not only plausible but, to many readers, quite convincing. As a commentary, it remains inherently descriptive and depends on previously published genomic and epidemiologic studies without providing new data or quantitative risk estimates. Important issues such as the comparative contribution of GPSC10 versus other lineages to residual IPD, or modelling of the potential impact of pediatric PCV20 or future pediatric PCV21, are only implied rather than explored. The discussion of policy implications remains relatively general; more concrete guidance on surveillance design, data sharing, and how to prioritize serotypes in next‑generation vaccines would strengthen its utility for ministries of health and advisory groups.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Zheng C, Zhang Y, Wang Y, et al. Two-case cluster of rapidly progressive influenza B and Staphylococcus aureus pneumonia with one death. Int J Infect Dis. 2026. doi: 10.1016/j.ijid.2026.108442

Summary
This case report describes two previously healthy construction workers (39 and 36 years) who developed fulminant pneumonia after a shared occupational exposure, with one fatal and one surviving case. Both dismantled a brick wall without respiratory protection and developed high fever, dry cough, and sore throat within 48 hours, consistent with an initial influenza‑like illness.

By day 5, Case 1 presented in extremis with diffuse bilateral consolidation and early cavitation on chest CT and died within hours of admission from respiratory failure; no microbiologic samples were obtained, but the pattern was highly suggestive of necrotizing pneumonia. Case 2 was admitted on day 6 with severe pneumonia, septic shock, and multi‑organ failure (lactic acidosis, acute kidney and liver injury, myocardial and skeletal muscle involvement), alongside extensive bilateral pulmonary infiltrates with right‑sided predominance. Initial external PCR testing yielded a complex mixture of signals (S. aureus and rhinovirus in blood; Klebsiella pneumoniae and rhinovirus in sputum), leading to empiric therapy with teicoplanin, meropenem, peramivir, and low‑dose corticosteroids.

In‑house metagenomic next‑generation sequencing (mNGS) of sputum, and later BALF, clarified the picture by identifying influenza B virus and Panton–Valentine leukocidin (PVL)–positive methicillin‑susceptible Staphylococcus aureus (MSSA) as the clinically relevant co‑pathogens, while reclassifying Klebsiella and rhinovirus as incidental. Despite transient improvement in systemic biomarkers (lactate, CRP, PCT), Case 2 developed persistent high‑grade fevers, rising leukocytosis, and radiographic progression to bilateral necrotizing pneumonia with cavitation, prompting bronchoscopy. BAL culture and mNGS confirmed abundant MSSA, and whole‑genome sequencing showed a PVL‑positive ST22 clone with a resistance profile limited to penicillin G, consistent with emerging community‑associated MSSA in China.

Teicoplanin was then replaced by linezolid to optimize lung tissue penetration, without other major changes in supportive care at that time. After this switch, fever and leukocytosis resolved, and CT on day 36 showed substantial radiological improvement, allowing discharge on day 38. The authors conclude that PVL‑positive MSSA, in synergy with influenza B, was the main driver of necrotizing lung injury and outcome, and they advocate for early mNGS and use of lung‑penetrant anti‑staphylococcal agents in similar scenarios.

Comment
This report is a compelling illustration of post‑influenza necrotizing pneumonia in previously healthy adults in which PVL‑producing MSSA, enabled by influenza‑mediated epithelial and innate‑immune disruption, is the dominant driver of fulminant lung destruction rather than “severe viral pneumonia” alone. The tightly aligned temporal data (brief flu‑like prodrome, abrupt respiratory collapse, early cavitation, leukopenia followed by marked neutrophilic rebound) and the mNGS‑based clarification of PVL‑positive ST22 MSSA plus influenza B as the true pathogen pair are major strengths, as is the pharmacologic rationale for switching from teicoplanin to linezolid, even though this remains an uncontrolled n=1 observation. Key limitations are the lack of microbiology in Case 1 and the absence of environmental or carriage studies, which preclude firm conclusions about transmission pathways. Clinically, the message is clear: in rapidly progressive, cavitating pneumonia after influenza, S. aureus—often PVL‑positive MSSA—should be assumed until disproven, with early deep sampling, high‑resolution diagnostics and lung‑penetrant anti‑staphylococcal therapy; more broadly, seasonal influenza vaccination, even in healthy young adults, may prevent not only viral illness but also such catastrophic bacterial superinfection and death.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Mitjà O, Marks M. Household transmission of mpox in Africa: limited in adults but more prevalent in children. Lancet Infect Dis. 2026;26(2):117‑118. doi:10.1016/S1473-3099(25)00503-1

Summary
This comment interprets a prospective household cohort study from Burundi that followed 88 PCR‑confirmed clade Ib mpox index cases and >430 household contacts over 3 weeks during an active outbreak. Fewer than one in four households experienced any secondary cases, and most index cases generated only a single additional infection, indicating that, overall, households played a limited role in sustaining transmission among adults. The nuance for pediatrics is critical: children <15 years had a secondary attack rate (SAR) about three times higher than adults (≈9% vs 3%), and their household reproduction number was similarly higher, reflecting closer physical contact, shared sleeping spaces, and difficulty isolating.

A sensitivity analysis that reclassified all pediatric “index” cases as secondary cases more than doubled estimated SAR and R₀, suggesting that adults are often the true primary cases but present later because of stigma or delayed care‑seeking, while children are detected earlier. Notably, there was no association between transmission and household crowding, water access, or rural vs urban residence, supporting the view that most adult infections occur outside the home (often via sexual or intimate contact), with children infected secondarily. Methodological strengths include PCR‑confirmed index cases, clear case–contact linkages, high follow‑up and rigorous fieldwork; limitations include the absence of serology (asymptomatic infection likely missed), restriction of testing to symptomatic contacts, and convenience sampling that may limit generalizability.

Why these articles matter for daily practice
Taken together, these two pieces sharpen the clinical lens through which pediatricians and general clinicians should view mpox. First, they argue against complacency about vaccine‑induced protection: in smallpox‑naïve adults and adolescents, a standard two‑dose MVA‑BN regimen may not generate long‑lived neutralizing antibodies, implying that risk groups (including some health‑care workers and high‑exposure populations) may need booster strategies and that route and dose (full‑dose subcutaneous rather than fractional intradermal) are not trivial implementation details but immunologically meaningful choices. Second, the Burundi household data reframe children not as the primary engine of mpox epidemics but as vulnerable “downstream” victims of adult infections acquired in extra‑household settings, which has direct implications for case‑finding, counselling and safeguarding: when a child presents with suspected mpox, the clinician should actively look for undiagnosed adult cases in the network, address stigma, and ensure that household infection‑control advice is realistically tailored to close contact between children and caregivers. For routine practice, this translates into more precise risk communication, careful vaccination counselling for at‑risk families and staff, and a low threshold to consider mpox in children with compatible rash illness in African and travel‑exposed settings, even when the presumed “index” is an adult with a non‑sexual exposure story.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Mitjà O, Marks M. The lasting lessons of mpox: infection, vaccination, and immune memory. Lancet Infect Dis. 2026;26(2):118‑119. doi:10.1016/S1473-3099(25)00596-1

Summary
This commentary reviews a 2‑year cohort of 250 adults with orthopoxvirus exposure (natural mpox infection vs MVA‑BN vaccination) and distils practical lessons on durability and quality of immune memory. Natural mpox infection induced robust neutralizing antibodies that remained detectable for up to 2 years, whereas individuals vaccinated with MVA‑BN—especially those born after cessation of smallpox vaccination in the 1970s—showed weak and rapidly waning functional antibody responses, with neutralizing antibodies detectable in only a small minority beyond 8 months. People who had received historic, replication‑competent smallpox vaccines (e.g. Dryvax) and were later vaccinated with MVA‑BN had antibody titers similar to convalescent mpox cases, underlining the long‑term imprinting by live‑replicating vaccinia vaccines.

For practicing clinicians, the key message is that current third‑generation MVA‑BN vaccines are very safe, including in immunocompromised patients, but probably provide shorter‑lived functional protection than natural infection or older smallpox vaccines. Subcutaneous administration at full dose elicited higher binding and neutralizing antibody titers than fractional intradermal dosing, arguing for standard‑dose subcutaneous schedules in smallpox‑naïve individuals whenever supply allows. The authors emphasize that next‑generation mpox/smallpox vaccines will need to balance safety with more durable neutralizing responses, likely by focusing on key MPXV antigens such as E8 and A35 and optimizing antigen dose and delivery.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI

Bibliography
Cohen M, Klein J, Montz E, Wong CA. The essential role of states in protecting immunization access. N Engl J Med. 2026;394(5):420‑422. doi:10.1056/NEJMp2517029

Summary
This Perspective outlines how recent U.S. federal policy shifts threaten long‑standing structures that guarantee broad, no‑cost access to recommended vaccines and how states can respond to protect immunization access. Historically, the FDA, CDC and ACIP have formed a coherent federal backbone: FDA licenses vaccines; ACIP issues evidence‑based recommendations; VFC and Affordable Care Act provisions then ensure no‑cost coverage and stable supply. The authors describe how this framework is being destabilized by the narrowing of Covid‑19 vaccine labels, ACIP votes to stop routine recommendations for Covid‑19 and thiomersal‑containing influenza vaccines without high‑quality supporting evidence, and website changes implying vaccine–autism links.

They highlight six main risk channels:

1. Loss of no‑cost coverage if ACIP rescinds or narrows recommendations, unless states explicitly tie coverage to professional society guidelines (e.g., AAP) as well.
2. Instability of the Vaccines for Children (VFC) program, because VFC eligibility is directly linked to the CDC schedule; removing or narrowing indications would abruptly cut off publicly purchased vaccines for millions of children.
3. Disruption of school and child‑care entry requirements, many of which are pegged to CDC/ACIP recommendations.
4. Constraints on who may vaccinate when scope‑of‑practice rules are tied to FDA labels or CDC recommendations.
5. Increased clinician liability concerns if changes to VICP or PREP Act protections are made, potentially discouraging vaccination in off‑label or “shared clinical decision‑making” contexts.
6. Expansion of “shared clinical decision‑making” language, which may reframe some vaccines as “optional,” increases documentation burden and confuses clinicians and the public.

The article then sets out an action agenda: states can mandate no‑cost coverage in Medicaid and regulated plans, build contingency procurement mechanisms (e.g,. Section 317 funds, state universal purchase), decouple school‑entry statutes from federal schedules by aligning instead with expert society recommendations, broaden vaccinator scope‑of‑practice, reaffirm liability protections, and invest in trusted messengers and surveillance for coverage and misinformation. While acknowledging that such efforts cannot fully replace coherent federal leadership, the authors argue that state action is essential to prevent backsliding to uneven vaccine access and resurgent vaccine‑preventable disease.

Comment: Global relevance
Although written for the current United States situation, this piece is a vivid case study of how vaccine access in practice is determined not only by national licensure and guidelines but by the decisions of sub‑national entities that control school requirements, procurement, reimbursement, and who is allowed to vaccinate. The dynamics describe fragile dependence on central technical bodies, rapid policy shifts driven by politics, and the need for local governments to improvise coverage, supply and communication strategies—are directly analogous to the situation in many countries where health and immunization are devolved to states, provinces, or even municipalities, often with limited in‑house vaccinology expertise. For clinicians and policy‑makers outside the U.S., the article is a reminder that robust vaccine access requires not just good science at the national level, but also strong, technically supported sub‑national governance that can buffer political shocks, maintain evidence‑based schedules, and prevent local gaps in expertise from eroding population protection.

Download PDF here.
Brought to you by Chief Editor Joe Schmitt – Supported by AI